Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells

Overview

Journal Mol Neurobiol

Specialties Molecular Biology
Neurology

Date 2017 Jun 15

PMID 28612256

Citations 11

Authors

Emilly Schlee Villodre

Franciele Cristina Kipper

Andrew Oliveira Silva

Guido Lenz

Patricia Luciana da Costa Lopez

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is an aggressive brain tumor with temozolomide (TMZ)-based chemotherapy as the main therapeutic strategy. Doxorubicin (DOX) is not used in gliomas due to its low bioavailability in the brain; however, new delivery strategies and low doses may be effective in the long term, especially as part of a drug cocktail. Our aim was to evaluate the chronic effects of low doses of DOX and TMZ in GBM. Human U87-ATCC cells and a primary GBM culture were chronically treated with TMZ (5 μM) and DOX (1 and 10 nM) alone or combined. DOX resulted in a reduction in the number of cells over a period of 35 days and delayed the cell regrowth. In addition, DOX induced cell senescence and reduced tumor sphere formation and the proportion of NANOG- and OCT4-positive cells after 7 days. Low doses of TMZ potentiated the effects of DOX on senescence and sphere formation. This combined response using low doses of DOX may pave the way for its use in glioma therapy, with new technologies to overcome its low blood-brain barrier permeability.

Citing Articles

Evaluation of Single and Combined Temozolomide and Doxorubicin Treatment Responses in Low- and High-Grade Glioma In Vitro.

Staicu G, Tataranu L, Tache D, Popescu S, Artene S, Danoiu S Cureus. 2024; 16(8):e66928.

PMID: 39280423 PMC: 11401637. DOI: 10.7759/cureus.66928.

The Temozolomide-Doxorubicin paradox in Glioblastoma in vitro-in silico preclinical drug-screening.

Oraiopoulou M, Tzamali E, Psycharakis S, Tzedakis G, Makatounakis T, Manolitsi K Sci Rep. 2024; 14(1):3759.

PMID: 38355655 PMC: 10866941. DOI: 10.1038/s41598-024-53684-y.

Inhibition of Protein Disulfide Isomerase (PDIA1) Leads to Proteasome-Mediated Degradation of Ubiquitin-like PHD and RING Finger Domain-Containing Protein 1 (UHRF1) and Increased Sensitivity of Glioblastoma Cells to Topoisomerase II Inhibitors.

Mouawad R, Neamati N ACS Pharmacol Transl Sci. 2023; 6(1):100-114.

PMID: 36654750 PMC: 9841782. DOI: 10.1021/acsptsci.2c00186.

Poly(ethylene glycol) based nanotubes for tuneable drug delivery to glioblastoma multiforme.

Alghamdi M, Chierchini F, Eigel D, Taplan C, Miles T, Pette D Nanoscale Adv. 2022; 2(10):4498-4509.

PMID: 36132909 PMC: 9418774. DOI: 10.1039/d0na00471e.

Chemosensitization of U-87 MG Glioblastoma Cells by Neobavaisoflavone towards Doxorubicin and Etoposide.

Maszczyk M, Banach K, Karkoszka M, Rzepka Z, Rok J, Beberok A Int J Mol Sci. 2022; 23(10).

PMID: 35628432 PMC: 9144651. DOI: 10.3390/ijms23105621.

References

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Almubarak M, Newton M, Altaha R . Reinduction of bevacizumab in combination with pegylated liposomal Doxorubicin in a patient with recurrent glioblastoma multiforme who progressed on bevacizumab/irinotecan. J Oncol. 2009; 2008:942618. PMC: 2648641. DOI: 10.1155/2008/942618. View

Zheng X, Cui D, Xu S, Brabant G, Derwahl M . Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells. Int J Oncol. 2010; 37(2):307-15. DOI: 10.3892/ijo_00000679. View

Allen M, Bjerke M, Edlund H, Nelander S, Westermark B . Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med. 2016; 8(354):354re3. DOI: 10.1126/scitranslmed.aaf6853. View

Denysenko T, Gennero L, Roos M, Melcarne A, Juenemann C, Faccani G . Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies. Cell Biochem Funct. 2010; 28(5):343-51. DOI: 10.1002/cbf.1666. View

Lundberg A, Hahn W, Gupta P, Weinberg R . Genes involved in senescence and immortalization. Curr Opin Cell Biol. 2000; 12(6):705-9. DOI: 10.1016/s0955-0674(00)00155-1. View

Silva A, Felipe K, Villodre E, Lopez P, Lenz G . A guide for the analysis of long-term population growth in cancer. Tumour Biol. 2016; 37(10):13743-13749. DOI: 10.1007/s13277-016-5255-z. View

Ohtani N, Hara E . Roles and mechanisms of cellular senescence in regulation of tissue homeostasis. Cancer Sci. 2013; 104(5):525-30. PMC: 7657106. DOI: 10.1111/cas.12118. View

Hammond L, Eckardt J, Baker S, Eckhardt S, Dugan M, Forral K . Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol. 1999; 17(8):2604-13. DOI: 10.1200/JCO.1999.17.8.2604. View

10.

Atashpour S, Fouladdel S, Movahhed T, Barzegar E, Ghahremani M, Ostad S . Quercetin induces cell cycle arrest and apoptosis in CD133(+) cancer stem cells of human colorectal HT29 cancer cell line and enhances anticancer effects of doxorubicin. Iran J Basic Med Sci. 2015; 18(7):635-43. PMC: 4556754. View

11.

Maher E, Furnari F, Bachoo R, Rowitch D, Louis D, Cavenee W . Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001; 15(11):1311-33. DOI: 10.1101/gad.891601. View

12.

Beier D, Schulz J, Beier C . Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. Mol Cancer. 2011; 10:128. PMC: 3207925. DOI: 10.1186/1476-4598-10-128. View

13.

Fan X, Salford L, Widegren B . Glioma stem cells: evidence and limitation. Semin Cancer Biol. 2006; 17(3):214-8. DOI: 10.1016/j.semcancer.2006.04.002. View

14.

Yu Z, Zhao G, Li P, Li Y, Zhou G, Chen Y . Temozolomide in combination with metformin act synergistically to inhibit proliferation and expansion of glioma stem-like cells. Oncol Lett. 2016; 11(4):2792-2800. PMC: 4812167. DOI: 10.3892/ol.2016.4315. View

15.

Zhang R, Saito R, Shibahara I, Sugiyama S, Kanamori M, Sonoda Y . Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells. J Neurooncol. 2015; 126(2):235-42. DOI: 10.1007/s11060-015-1968-x. View

16.

Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G . Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 2006; 13(7):1238-41. DOI: 10.1038/sj.cdd.4401872. View

17.

Goncalves C, Martins-Neves S, Paiva-Oliveira D, Oliveira V, Fontes-Ribeiro C, Gomes C . Sensitizing osteosarcoma stem cells to doxorubicin-induced apoptosis through retention of doxorubicin and modulation of apoptotic-related proteins. Life Sci. 2015; 130:47-56. DOI: 10.1016/j.lfs.2015.03.009. View

18.

Dumont P, Burton M, Chen Q, Gonos E, Frippiat C, Mazarati J . Induction of replicative senescence biomarkers by sublethal oxidative stresses in normal human fibroblast. Free Radic Biol Med. 2000; 28(3):361-73. DOI: 10.1016/s0891-5849(99)00249-x. View

19.

Beier D, Rohrl S, Pillai D, Schwarz S, Kunz-Schughart L, Leukel P . Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 2008; 68(14):5706-15. DOI: 10.1158/0008-5472.CAN-07-6878. View

20.

Filippi-Chiela E, Oliveira M, Jurkovski B, Callegari-Jacques S, da Silva V, Lenz G . Nuclear morphometric analysis (NMA): screening of senescence, apoptosis and nuclear irregularities. PLoS One. 2012; 7(8):e42522. PMC: 3414464. DOI: 10.1371/journal.pone.0042522. View